TL;DR
This approach establishes a biologically informed framework for stratifying recurrence risk based on RNA-seq data, potentially enhancing riskadapted surveillance and postoperative management for HCC.
Hepatocellular carcinoma (HCC) is one of the malignant tumors with high incidence and mortality rates worldwide. Given the poor prognosis of patients with HCC, it is crucial to explore the molecular mechanisms underlying HCC development and to evaluate prognostic markers. Differential expression analysis followed by un...
IntClust can be inferred from routine clinical sequencing and resolves survival heterogeneity not captured by ER or HER2, and reveals subtype-specific contexts for prognostic effects of the same mutation drivers, and for acquisition of ESR1 mutations.
Although the clinical utility of the TMBRS is currently moderate, this research provides a critical proof of concept for the interplay among PTGS2, mutational load, and the tumor microenvironment, offering valuable mechanistic insights for future large-scale prospective clinical trials.
The results show that patients who received chemotherapy demonstrated a shorter median RFS compared to those who did not, and radiotherapy was associated with improved prognosis, in line with meta-analyses showing reduced breast cancer mortality post-radiotherapy.
A six-gene-fibrosis-based prognostic model based on six genes stratifies survival risk and correlates with immune features and drug sensitivity, but provides a preliminary framework requiring prospective clinical validation.
A READ-derived response-associated gene signature for recurrence stratification and exploratory cross-cohort evaluation in additional colorectal cancer cohorts, while further exploring its association with treatment-response phenotypes.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
